Alkermes

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Alkermes and other ETFs, options, and stocks.

About ALKS

Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. 

CEO
Richard F. Pops
CEORichard F. Pops
Employees
2,050
Employees2,050
Headquarters
Dublin, Dublin
HeadquartersDublin, Dublin
Founded
2011
Founded2011
Employees
2,050
Employees2,050

ALKS Key Statistics

Market cap
8.62B
Market cap8.62B
Price-Earnings ratio
57.74
Price-Earnings ratio57.74
Dividend yield
Dividend yield
Average volume
1.62M
Average volume1.62M
High today
High today
Low today
Low today
Open price
$52.96
Open price$52.96
Volume
0.00
Volume0.00
52 Week high
$55.67
52 Week high$55.67
52 Week low
$25.17
52 Week low$25.17

Stock Snapshot

With a market cap of 8.62B, Alkermes(ALKS) trades at $51.72. The stock has a price-to-earnings ratio of 57.74.

During the trading day, Alkermes(ALKS) stock saw an opening price of $52.96, a peak of —, and a bottom of —.

Trading activity shows a volume of 0, compared to an average daily volume of 1.62M.

Over the past 52 weeks, Alkermes(ALKS) stock has traded between a high of $55.67 and a low of $25.17.

Over the past 52 weeks, Alkermes(ALKS) stock has traded between a high of $55.67 and a low of $25.17.

ALKS News

CNN 5h
symbol__ Stock Quote Price and Forecast - CNN

...

symbol__ Stock Quote Price and Forecast - CNN
TipRanks 1d
Alkermes price target raised to $63 from $45 at Stifel

Stifel raised the firm’s price target on Alkermes (ALKS) to $63 from $45 and keeps a Buy rating on the shares. Shares have had a significant run, largely on the...

Simply Wall St 4d
Alkermes Following Alixorexton Data, Is The Bull Case Already Priced In?

Alkermes (ALKS) recently reported interim data from its long term extension study of alixorexton in narcolepsy and idiopathic hypersomnia, highlighting sustaine...

Alkermes Following Alixorexton Data, Is The Bull Case Already Priced In?

Analyst ratings

76%

of 17 ratings
Buy
76.5%
Hold
17.6%
Sell
5.9%

More ALKS News

Simply Wall St 5d
Sustained Alixorexton Narcolepsy Data Could Be A Game Changer For Alkermes

Alkermes plc recently reported interim results from a long‑term extension study showing its investigational orexin 2 receptor agonist alixorexton maintained cli...

Sustained Alixorexton Narcolepsy Data Could Be A Game Changer For Alkermes

People also own

Based on the portfolios of people who own ALKS. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.